A Phase 1 Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, Administered With a Fixed Dose of VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Relapsed Malignant Mesothelioma
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Defactinib (Primary) ; VS 5584 (Primary)
- Indications Mesothelioma
- Focus Adverse reactions
- Sponsors Verastem
- 03 Jan 2017 Status changed from active, no longer recruiting to discontinued.
- 19 Oct 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 10 Sep 2015 According to a Verastem media release, data from this study will be presented at the 16th World Conference on Lung Cancer (WCLC).